Fluorouracil

Breast Cancer, Carcinoma, Basal Cell, Rectal Cancer + 6 more
Treatment
1 FDA approval
20 Active Studies for Fluorouracil

What is Fluorouracil

FluorouracilThe Generic name of this drug
Treatment SummaryCapecitabine is a type of medication used to treat cancer. It works by interfering with the process of DNA synthesis and preventing the growth of cancer cells.
Efudexis the brand name
image of different drug pills on a surface
Fluorouracil Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Efudex
Fluorouracil
1970
62

Approved as Treatment by the FDA

Fluorouracil, also known as Efudex, is approved by the FDA for 1 uses like Actinic keratosis .
Actinic keratosis
Used to treat hyperkeratotic actinic keratosis in combination with Salicylic acid

Effectiveness

How Fluorouracil Affects PatientsFluorouracil is a drug that helps stop cancer cells from growing. It does this by preventing the building blocks of DNA (purine and pyrimidine) from being incorporated into the DNA during the "S" phase of the cell cycle. Fluorouracil also blocks an enzyme that changes a type of nucleotide into the deoxy derivative, and it stops the incorporation of the thymidine nucleotide into the DNA strand, which stops DNA synthesis.
How Fluorouracil works in the bodyFluorouracil works by binding to an enzyme called thymidylate synthase. This prevents the formation of a compound used in DNA and RNA synthesis, which leads to cell death. It can also interfere with protein production by taking the place of a compound normally used in RNA processing.

When to interrupt dosage

The proposed dose of Fluorouracil is contingent upon the diagnosed malady, such as Actinic Keratosis, Verruca (Warts) and non-immunocompromised. The amount of dosage can be found in the table beneath, contingent upon the method of delivery (e.g. Solution - Topical or Injection, solution).
Condition
Dosage
Administration
Actinic Keratosis
, 50.0 mg/mL, 0.005 mg/mg, 0.05 mg/mg, 0.04 mg/mg, 20.0 mg/mL, 5.0 %, 1.0 %, 0.5 %, 250.0 mg/mL, 0.01 mg/mg, 0.2 mg/mg, 10.0 mg/mL, 5.0 mg/mg, 125.0 mg/mL, 4.0 %, 100.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Cream - Topical, Topical, Cream, Solution - Topical, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, Injection - Intravenous, Kit
Breast Cancer
, 50.0 mg/mL, 0.005 mg/mg, 0.05 mg/mg, 0.04 mg/mg, 20.0 mg/mL, 5.0 %, 1.0 %, 0.5 %, 250.0 mg/mL, 0.01 mg/mg, 0.2 mg/mg, 10.0 mg/mL, 5.0 mg/mg, 125.0 mg/mL, 4.0 %, 100.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Cream - Topical, Topical, Cream, Solution - Topical, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, Injection - Intravenous, Kit
Warts
, 50.0 mg/mL, 0.005 mg/mg, 0.05 mg/mg, 0.04 mg/mg, 20.0 mg/mL, 5.0 %, 1.0 %, 0.5 %, 250.0 mg/mL, 0.01 mg/mg, 0.2 mg/mg, 10.0 mg/mL, 5.0 mg/mg, 125.0 mg/mL, 4.0 %, 100.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Cream - Topical, Topical, Cream, Solution - Topical, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, Injection - Intravenous, Kit
Actinic keratosis
, 50.0 mg/mL, 0.005 mg/mg, 0.05 mg/mg, 0.04 mg/mg, 20.0 mg/mL, 5.0 %, 1.0 %, 0.5 %, 250.0 mg/mL, 0.01 mg/mg, 0.2 mg/mg, 10.0 mg/mL, 5.0 mg/mg, 125.0 mg/mL, 4.0 %, 100.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Cream - Topical, Topical, Cream, Solution - Topical, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, Injection - Intravenous, Kit
Carcinoma, Basal Cell
, 50.0 mg/mL, 0.005 mg/mg, 0.05 mg/mg, 0.04 mg/mg, 20.0 mg/mL, 5.0 %, 1.0 %, 0.5 %, 250.0 mg/mL, 0.01 mg/mg, 0.2 mg/mg, 10.0 mg/mL, 5.0 mg/mg, 125.0 mg/mL, 4.0 %, 100.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Cream - Topical, Topical, Cream, Solution - Topical, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, Injection - Intravenous, Kit
Stomach Cancer
, 50.0 mg/mL, 0.005 mg/mg, 0.05 mg/mg, 0.04 mg/mg, 20.0 mg/mL, 5.0 %, 1.0 %, 0.5 %, 250.0 mg/mL, 0.01 mg/mg, 0.2 mg/mg, 10.0 mg/mL, 5.0 mg/mg, 125.0 mg/mL, 4.0 %, 100.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Cream - Topical, Topical, Cream, Solution - Topical, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, Injection - Intravenous, Kit
Rectal Cancer
, 50.0 mg/mL, 0.005 mg/mg, 0.05 mg/mg, 0.04 mg/mg, 20.0 mg/mL, 5.0 %, 1.0 %, 0.5 %, 250.0 mg/mL, 0.01 mg/mg, 0.2 mg/mg, 10.0 mg/mL, 5.0 mg/mg, 125.0 mg/mL, 4.0 %, 100.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Cream - Topical, Topical, Cream, Solution - Topical, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, Injection - Intravenous, Kit
Colon Cancer
, 50.0 mg/mL, 0.005 mg/mg, 0.05 mg/mg, 0.04 mg/mg, 20.0 mg/mL, 5.0 %, 1.0 %, 0.5 %, 250.0 mg/mL, 0.01 mg/mg, 0.2 mg/mg, 10.0 mg/mL, 5.0 mg/mg, 125.0 mg/mL, 4.0 %, 100.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Cream - Topical, Topical, Cream, Solution - Topical, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, Injection - Intravenous, Kit
Pancreatic Cancer
, 50.0 mg/mL, 0.005 mg/mg, 0.05 mg/mg, 0.04 mg/mg, 20.0 mg/mL, 5.0 %, 1.0 %, 0.5 %, 250.0 mg/mL, 0.01 mg/mg, 0.2 mg/mg, 10.0 mg/mL, 5.0 mg/mg, 125.0 mg/mL, 4.0 %, 100.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Cream - Topical, Topical, Cream, Solution - Topical, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, Injection - Intravenous, Kit

Warnings

Fluorouracil Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
There are 20 known major drug interactions with Fluorouracil.
Common Fluorouracil Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Fluorouracil is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Fluorouracil is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abetimus
Major
The risk or severity of adverse effects can be increased when Fluorouracil is combined with Abetimus.
Acenocoumarol
Major
The metabolism of Acenocoumarol can be decreased when combined with Fluorouracil.
Acteoside
Major
The risk or severity of adverse effects can be increased when Fluorouracil is combined with Acteoside.
Fluorouracil Toxicity & Overdose RiskThe lowest toxic dose in mice when taken orally is 230mg/kg.
image of a doctor in a lab doing drug, clinical research

Fluorouracil Novel Uses: Which Conditions Have a Clinical Trial Featuring Fluorouracil?

1138 active trials are currently assessing Fluorouracil's potential as a therapeutic agent in Stomach Cancer, Colon Cancer and Rectal Cancer.
Condition
Clinical Trials
Trial Phases
Stomach Cancer
161 Actively Recruiting
Phase 2, Phase 3, Phase 1, Not Applicable, Early Phase 1, Phase 4
Pancreatic Cancer
171 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Phase 1, Early Phase 1, Phase 4
Rectal Cancer
43 Actively Recruiting
Phase 3, Phase 2, Not Applicable, Phase 1
Colon Cancer
55 Actively Recruiting
Not Applicable, Phase 1, Phase 2
Breast Cancer
21 Actively Recruiting
Phase 2, Phase 1, Not Applicable
Actinic keratosis
0 Actively Recruiting
Carcinoma, Basal Cell
0 Actively Recruiting
Warts
0 Actively Recruiting
Actinic Keratosis
10 Actively Recruiting
Not Applicable, Phase 2, Phase 3, Phase 1, Phase 4

Fluorouracil Reviews: What are patients saying about Fluorouracil?

5Patient Review
2/25/2022
Fluorouracil for Roughened Red Patches of Skin due to Sun Exposure
I'm only on day 12 of the treatment, and I've already started to see results. There are still some red patches on my forehead and temples, but they're starting to itch now so I know the worst is yet to come. However, this is a small price to pay for the stupidity of not protecting myself from the sun while playing golf in my 30s.
5Patient Review
4/16/2022
Fluorouracil for Superficial Basal Cell Carcinoma of the Skin
I've used this medication a few times now and have had great results. I simply apply it to a small area of my face, wait for the skin to start breaking down, then cover with a bandaid. After the skin heals, I can move on to another spot. It's time-consuming, but it works wonders!
5Patient Review
3/6/2022
Fluorouracil for Superficial Basal Cell Carcinoma of the Skin
While this treatment is incredibly difficult, it's still the best option out there. I've been using it for over 30 years to combat basal and squamous cell carcinoma.
5Patient Review
7/20/2022
Fluorouracil for Superficial Basal Cell Carcinoma of the Skin
I'm really confused by the negative reviews for this product. I followed the instructions to a T and found that it worked great for me. The spot turned red, scabbed over, and then disappeared. It was easy to use, painless, and avoided surgery.
5Patient Review
2/12/2022
Fluorouracil for Roughened Red Patches of Skin due to Sun Exposure
Despite an initial breakout and some discomfort, this treatment really helped my skin regenerate. I would recommend using Aquaphor to help soothe the skin afterwards.
4.7Patient Review
9/19/2022
Fluorouracil for Superficial Basal Cell Carcinoma of the Skin
I've been using this treatment on and off for a decade, and it really works wonders. I usually only do the full scalp treatment when absolutely necessary, as it can be painful. The process isn't pretty, but wearing a hat while you're out and about will help hide it from others until it's done. Once the treatment is finished, I make sure to keep an eye out for any dry or scabby patches so that I can spot treat them immediately.
4Patient Review
10/7/2022
Fluorouracil for Superficial Basal Cell Carcinoma of the Skin
Just finished my six week treatment after only a small amount of cancer remained after removal. I was expecting the redness, itching, and tenderness, as well as the scales. The small discomfort wasn't bad at all. Been in the sun all my life. Now go out with long sleeve shirts that have UV protection. Bald head always has a hat, and will wear bucket for extra for head and ears. Sunscreen on ears, nose and anything exposed.
3Patient Review
8/2/2022
Fluorouracil for Roughened Red Patches of Skin due to Sun Exposure
I unfortunately had pre-cancerous spots on my lips, so I began using the F. Cream. It's been a nightmare because it has made my lips incredibly sore and sensitive. Almost impossible to eat or drink without pain, and smiling is out of the question. One more week to go and hopefully this will be resolved.
1Patient Review
2/4/2022
Fluorouracil for Roughened Red Patches of Skin due to Sun Exposure
I would never recommend this facial treatment to anyone. I went through the application process and recovery only to see a very small improvement. If you have a sedentary lifestyle, it may be OK (other than continuous sleepless nights). If you are an active, outdoors person, standby for "hell."
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about fluorouracil

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does fluorouracil do to your skin?

"This medication is used to treat pre-cancerous and cancerous skin growths by causing the death of abnormal cells."

Answered by AI

How long does it take for fluorouracil to start working?

"It usually takes at least 3 weeks for the medication to work, but it may take as long as 12 weeks. The skin around the area where the medication is applied will look red, swollen, and scaly during the first few weeks of treatment, which is a sign that the medication is working."

Answered by AI

What is fluorouracil used to treat?

"Fluorouracil topical is a medication used to treat actinic or solar keratoses and a type of skin cancer called superficial basal cell carcinoma. This medicine is available only with a doctor's prescription. This product is available in cream form."

Answered by AI

Is fluorouracil a chemotherapy drug?

"Fluorouracil belongs to a class of chemotherapy drugs called anti metabolites. Anti metabolites are similar to normal body molecules, but they have a slightly different structure. These differences mean that anti metabolites can inhibit the function of cancer cells."

Answered by AI

Clinical Trials for Fluorouracil

Image of Memorial Sloan Kettering Basking Ridge (Consent Only) in Basking Ridge, United States.

Multiparametric Ultrasound for Cancer

18+
All Sexes
Basking Ridge, NJ
The researchers are doing this study to see how well a type of ultrasound imaging called multiparametric ultrasound (mpUS), can be used to examine, evaluate, and provide information about different cancerous and non-cancerous tissue. The researchers will compare the results of mpUS imaging to standard ultrasound imaging and other standard tests. mpUS imaging is a type of ultrasound imaging that combines different ultrasound methods and analysis to create a more detailed and accurate assessment of tissue. Standard ultrasound provides a basic image of tissue structure, but mpUS imaging can also show blood vessels, blood flow, and detailed tissue structure (microstructure). The researchers think that mpUS may be a better way for evaluating cancer because it combines different ultrasound methods to assess tissue.
Recruiting
Has No Placebo
Memorial Sloan Kettering Basking Ridge (Consent Only) (+6 Sites)Mark T Burgess, MD
Have you considered Fluorouracil clinical trials? We made a collection of clinical trials featuring Fluorouracil, we think they might fit your search criteria.Go to Trials
Image of BAMF Health in Grand Rapids, United States.

GEH300079 PET/CT for Colorectal Cancer

18+
All Sexes
Grand Rapids, MI
This study is a Phase 2/3, prospective, multicenter, open-label, non-randomized clinical trial, in which GEH300079 (68Ga) PET/CT images will be acquired in patients with primary colorectal, gastric, ovarian, or Pancreatic Ductal Adenocarcinoma (PDAC) cancers and known or suspected Peritoneal Carcinomatosis (PC) before or after institutional Standard of Care (SoC) imaging. The primary objective is to evaluate the diagnostic performance of GEH300079 (68Ga) PET/CT for the detection of PC in patients with colorectal, gastric, or ovarian primary cancers, using a composite standard of truth (SoT), in a region-based analysis. The detection of PC in patients with primary PDAC will be explored in the Phase 2 part of the study. The study is comprised of 2 distinct parts: Phase 2 aims to confirm the statistical and scientific assumptions for the Phase 3 part, and to confirm the optimal dose and timing of acquisition of GEH300079 (68Ga) PET/CT in the PC indication. Phase 2 includes 2 cohorts: Cohort A (participants with colorectal, ovarian and gastric primary cancer), and Cohort B (participants with primary PDAC), where analysis of Cohort B is descriptive only. Phase 3 aims to demonstrate the safety and efficacy of GEH300079 (68Ga) PET/CT for the detection of PC in patients with confirmed colorectal, gastric or ovarian primary cancers.
Phase 2 & 3
Waitlist Available
BAMF HealthGE Healthcare
Image of Carolina Biooncology in Huntersville, United States.

RNDO-564 + Pembrolizumab for Bladder Cancer

18+
All Sexes
Huntersville, NC
The main goal of this study is to evaluate how safe and tolerable RNDO-564 is and to identify the best dose of RNDO-564 as a single agent and in combination with pembrolizumab. The study is focused on participants with certain solid tumors that are in an advanced stage and have certain tumor makers. This will be done by measuring the side effects that participants experience and how severe they are. Additionally, the study will evaluate how RNDO-564 moves into, through, and out of the body and how the treatment affects the body. The second goal of this study is to evaluate how well RNDO-564 works by itself or in combination with pembrolizumab at treating participants' cancer. This will be done by measuring the number of participants who respond to the treatment. The length of time where the tumor does not grow or spread will also be measured. Participants will take RNDO-564 weekly on Days 1, 8 and 15 of a 21 day cycle. Participants in the combination arms will take RNDO-564 as described with pembrolizumab every 3 weeks.
Phase 1
Recruiting
Carolina Biooncology (+1 Sites)Thomas Manley, MDRondo Therapeutics
Image of Helios CR Inc./RadNet in Cerritos, United States.

[18F]FAPI-74 PET for Stomach and Esophageal Cancer

18+
All Sexes
Cerritos, CA
This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of \[¹⁸F\]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically confirmed gastric, gastroesophageal junction or esophageal cancer. Following screening, using a standardized administration protocol and dose, participants will undergo \[¹⁸F\]FAPI-74 PET/CT screening. SOC procedures and interventions will be captured during 3 months +/-14 days post injection. The primary objective is to evaluate the sensitivity and specificity of such \[¹⁸F\]FAPI-74 PET/CT using a composite SOT panel. The maximum expected duration of the trial is approximately 24 months from first patient screening to last patient SOC follow up. The participants will be followed-up for safety for 24 to 72 hours after the dose of \[¹⁸F\]FAPI-74 PET/CT.
Phase 3
Recruiting
Helios CR Inc./RadNetSherly Mosessian, Ph.DSOFIE
Have you considered Fluorouracil clinical trials? We made a collection of clinical trials featuring Fluorouracil, we think they might fit your search criteria.Go to Trials
Have you considered Fluorouracil clinical trials? We made a collection of clinical trials featuring Fluorouracil, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security